Crisdesalazine ( AAD-2004;AAD2004 )

Catalog No. M16640 CAS No. 927685-43-6

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Crisdesalazine
Note

Research use only, not for human use.
Brief Description

Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.
Description

Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro; blocked free radical production, PGE(2) formation, and microglial activation in the spinal cords in superoxide dismutase 1(G93A) transgenic mouse model of ALS, reduced autophagosome formation, axonopathy, and motor neuron degeneration, improving motor function and increasing life span, which is superior to riluzole or ibuprofen.Alzheimer Disease Phase 1 Clinical
Synonyms

AAD-2004;AAD2004
Pathway

Immunology/Inflammation
Target

PGE synthase
Recptor

PGE synthase
Research Area

Neurological Disease
Indication

Alzheimer Disease

CAS Number

927685-43-6
Formula Weight

325.29
Molecular Formula

C16H14F3NO3
Purity

>98% (HPLC)
Solubility

——
SMILES

O=C(O)C1=CC(NCCC2=CC=C(C(F)(F)F)C=C2)=CC=C1O
Chemical Name

2-hydroxy-5-({2-[4-(trifluoromethyl)phenyl]ethyl}amino)benzoic acid

1. Shin JH, et al. J Neurochem. 2012 Sep;122(5):952-61.
2. Baek IS, et al. Exp Neurobiol. 2013 Mar;22(1):31-7.

Calculator

molnova catalog